MEGACE 160 mg Tablets
Megestrol acetate
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
1.What Megace tablets are and what they are used for
2.What you need to know before you take Megace tablets
3.How to take Megace tablets
4.Possible side effects
5.How to store Megace tablets
6 . Contents of the pack and other information
The name of your medicine is Megace tablets. Megace tablets contain the active ingredient megestrol acetate. Megestrol acetate belongs to a group of medicines called progestogens and is used to treat certain types of cancer known as hormone-dependent cancer, which include cancer of the breast.
- are allergic to megestrol acetate or any of the other ingredients of this medicine (listed in section 6).
Tell your doctor if you:
- have severe liver problems
- currently suffer from, or have a history of suffering from blood clots (thrombophlebitis)
- have diabetes, as Megace tablets can increase your blood sugar levels
If you are over 65 years of age your doctor may want to monitor your kidney function from time to time, as this can sometimes decrease with age.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not take Megace tablets if you are pregnant, think you may be pregnant, or if you are breast-feeding.
Megace tablets do not usually affect your ability to drive.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Always take Megace tablets exactly as your doctor has told you. You should check with your doctor if you are not sure.
The usual dosage is 160 mg megestrol acetate per day.
Tablets should be swallowed with a glass of water.
This medicine is not recommended for children.
Megace tablets should be taken for at least two months to see if they are effective. Some patients take them for many years.
Do not stop taking them, unless advised to do so by your doctor.
If you take more Megace than you should, go to your nearest hospital emergency department or contact your doctor immediately.
Take the empty container and any remaining medicine with you.
If you miss a dose, do not worry. If you remember within a few hours of the missed dose take it as soon as possible, but if it is almost time for your next dose then skip the forgotten one and continue as before. Do not take a double dose to make up for the one you missed.
As with all medicines, Megace can cause side effects although not everybody gets them.
If you notice any of the following, stop taking Megace and contact your doctor immediately:
- swelling of the face, lips, or tongue
- skin rash
- difficulty breathing
As these may be signs of an allergic reaction.
Other side effects which may occur with Megace tablets are:
Very Common (affects more than 1 in 10 people)
- increase in appetite and weight gain (not associated with water retention)
- shortness of breath
- hot flushes, reddening of the face and neck
- high blood pressure
- increased blood sugar levels
- rounded face, sometimes called 'moon' face
- constipation
- swelling of a vein due to a blood clot
- blood clot in the lungs
Signs of a blood clot can include loss of co-ordination, slurred speech, pains in your groin, pains or numbness in your arm or leg (especially in calf of leg), shortness of breath, weakness, headache, and fainting. If you experience any of these signs tell your doctor immediately.
Common (affects between 1 in 10 to 1 in 100 people)
- temporary increase in the signs and symptoms of your disease.
- changes in mood
- numbness, pain or tingling in fingers or thumb
- heart attack
- hair loss
- diarrhoea
- tiredness
- feeling weak
- impotence
- passing wind
- needing to urinate more often
- feeling sick and being sick
- changes in vaginal bleeding (breakthrough bleeding, spotting)
- build up of fluid which causes swelling (mainly in the ankles)
- pain
- rash, including hives or nettle rash (urticaria)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see contact details below). By reporting side effects you can help provide more information on the safety of this medicine.
Ireland:
HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
United Kingdom:
Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Do not store above 25°C. Store in the original package in order to protect from moisture. They should not get too hot or damp; so do not leave your tablets near a radiator, on a window sill or in the bathroom.
Please check the expiry date of the product, shown on the carton and blister of Megace tablets. Do not use after the month stated.
Keep this medicine out of the sight and reach of children.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Each Megace tablet contains 160 mg of the active ingredient megestrol acetate. The other ingredients are: microcrystalline cellulose, lactose monohydrate 224.5 mg, magnesium stearate, povidone, colloidal anhydrous silica, and sodium starch glycolate.
Megestrol acetate tablets (160 mg) are oval shaped biconvex tablets scored on one side and engraved with “160” on the other side and are available in blister packs of 30 tablets.
Marketing Authorisation Holder
UK:
Bausch Health Ireland Limited
3013 Lake Drive
Citywest Business Campus
Dublin 24
D24PPT3
Ireland
Manufacturer
Haupt Pharma Amareg GmbH
Donaustaufer Strasse 378
93055 Regensburg
Germany
This leaflet was last revised in September 2022
P1UK01